Physician and Drug Policy Expert is Outstanding Leadership Choice
Washington, DC – March 16, 2017 – The Community Oncology Alliance (COA) welcomes and strongly supports the nomination of Dr. Scott Gottlieb to serve as commissioner of the United States Food and Drug Administration (FDA).
“Dr. Gottlieb’s deep experience as a physician, policy maker, thought leader, cancer survivor, and advocate afford him exceptional insights into the critical role that the FDA plays in our nation’s health care system,” says Dr. Jeffrey Vacirca, president of COA and CEO of NY Cancer Specialists.
From his time serving as a former deputy commissioner at the FDA during the administration of President George W. Bush and senior policy advisor to the Administrator at the Centers for Medicare & Medicaid Services (CMS), Dr. Gottlieb is intimately familiar with how government works – and sometimes does not – for patients and physicians on the front lines of medical care, especially cancer treatment.
Dr. Gottlieb will provide strong, certain leadership to the FDA, an agency that is a critical part in our nation’s battle against cancer. He will have his hands full modernizing and strengthening the agency which has come under justifiable scrutiny for the high cost, regulatory hurdles, and length of approval times of cutting-edge, safe, and effective treatments for patients with cancer and other life-threatening illnesses.
Dr. Gottlieb has also demonstrated a keen understanding of the challenges our current drug supply system faces, such as the role that 340B drug pricing discounts and pharmacy benefit manager rebates play in pushing the cost of cancer care higher for all Americans. This insight will be instrumental as Dr. Gottlieb advises the administration of President Donald Trump around the challenges of high drug costs.
COA looks forward to working closely with Dr. Gottlieb at the FDA and calls on Congress to consider and approve his nomination without delay.